iÅ‹ß‚̘_•¶j

Zhang P, Tsuchiya K, Kinoshita T, Kushiyama H, Suidasari S, Hatakeyama M, Imura H, Kato N, Suda T.: Vitamin B6 prevents IL-1ƒÀ production by inhibiting NLRP3 inflammasome activation. J Biol Chem. 2016, in press

Kinoshita, T., Imamura, R., Kushiyama, H., and Suda, T.: NLRP3 mediates NF-ƒÈB activation and cytokine induction in microbially induced and sterile inflammation. PLoS One. 2015, 10(3):e0119179

Wang, Q., Imamura, R., Motani, K., Kushiyama, H., Nagata, S., and Suda, T. Pyroptotic cells externalize eat-me and release find-me signals and are efficiently engulfed by macrophages. Int. Immunol. 2013, 25(6):363-372.

Harashima, N., Inao, T., Imamura, R., Okano, S., Suda, T., and Harada, M.: Roles of the PI3K/Akt pathway and autophagy in TLR3 signaling-induced apoptosis and growth arrest of human prostate cancer cells. Cancer Immunol. Immunother. 2012, 61(5):667-676

Motani K, Kushiyama H, Imamura R, Kinoshita T, Nishiuchi T, and Suda T.FCaspase-1 induces apoptosis-associated speck-like protein containing a caspase-recruitment domain (ASC)-mediated necrosis independently of its catalytic activity. J Biol Chem. 2011

Motani, K., Kawase, K., Imamura, R., Kinoshita, T., Kushiyama, H., and Suda, T.: Activation of ASC induces apoptosis or necrosis, depending on the cell type, and causes tumor eradication. Cancer Sci., 2010, 101(8):1822-1827.

Imamura, R., Wang, Y., Kinoshita, T., Suzuki, M., Noda, T., Sagara, J., Taniguchi, S., Okamoto, H., and Suda, T.: Anti-inflammatory activity of PYNOD and its mechanism in humans and mice. J. Immunol., 2010, 184(10):5874-5884.

Hasegawa, M., Imamura, R., Motani, K., Nishiuchi, T., Matsumoto, N., Kinoshita, T., and Suda, T.: Mechanism and repertoire of ASC-mediated gene expression. J. Immunol., 2009, 182(12):7655-7662.

Ohno, S.,@Kinoshita, T., Ohno, Y., Minamoto, T., Suzuki N., Inoue M., and Suda, T.: Expression of NLRP7 (PYPAF3, NALP7) protein in endometrial cancer tissues. Anticancer Res., 2008, 28(4C):2493-2497.

Matsumoto, N., Imamura, R., Suda, T.: Caspase-8- and JNK-dependent AP-1 activation is required for Fas ligand-induced IL-8 production. FEBS J. 2007, 274:2376-2384.

Umemura, M., Yahagi, A., Hamada, S., Begum, M. D., Watanabe, H., Kawakami, K., Suda, T., Sudo, K., Nakae, S., Iwakura, Y., and Matsuzaki, G.: IL-17-mediated regulation of innate and acquired immune response against pulmonary Mycobacterium bovis BCG infection, J. Immunol., 2007, 2007, 178:3786-3796.

Hasegawa, M., Kawase, K., Inohara, N., Imamura, R., Yeh, W-C.,Kinoshita, T., and Suda, T.: Mechanism of ASC-mediatedapoptosis: Bid-dependent apoptosis in type II cells, Oncogene, 2007, 26:1748-1756.

Fujisawa, A., Kambe, N., Saito, M., Nishikomori, R., Tanizaki, H., Kanazawa, N., Adachi, S., Heike, T., Sagara, J., Suda, T., Nakahata, T., Miyachi, Y.: Disease-associated mutations in CIAS1 induce cathepsin B-dependent rapid cell death of human THP-1 monocytic cells, Blood, 2007, 109:2903-2911.

Kinoshita, T., Kondoh, C., Hasegawa, M., Imamura, R., and Suda, T.: Fas-associated Factor 1 is a negative regulator of PYRIN-containing Apaf-1-like protein 1, Int. Immunol., 2006, 18:1701-1706.

El Kasmi, K.C., Holst J, Coffre, M., Mielke, L., de Pauw, A., Lhocine, N., Smith, A.M., Rutschman, R., Kaushal, D., Shen, Y., Suda, T., Donnelly, R.P., Myers, M.G. Jr., Alexander, W., Vignali, D.A., Watowich, S.S., Ernst, M., Hilton, D.J., Murray, P.J.: General nature of the STAT3-activated anti-inflammatory response. J. Immunol., 2006, 177:7880-7888.

Kidoya, H., Umemura, U., Kawabe, T., Matsuzaki, G., Yahagi, A., Imamura,R., and Suda, T.: Fas ligand induces cell-autonomous IL-23 production indendritic cells, a mechanism for Fas ligand-induced IL-17 production. J.Immunol., 2005, 175:8024-31.

Kinoshita, T., Wang, Y., Hasegawa, M., Imamura, R., and Suda, T.: PYPAF3, a PYRIN-containing APAF-1-like protein, is a feedback regulator ofcaspase-1-dependent interleukin-1² secretion. J.Biol. Chem., 2005, 280:21720-5

Hasegawa M, Imamura R, Kinoshita T, Matsumoto N, Masumoto J, Inohara N,and Suda T.: ASC-mediated NF-ºB activation leading to interleukin-8production requires caspase-8 and is inhibited by CLARP. J.Biol. Chem., 2005, 280: 15122-30.

Imamura, R., Konaka, K., Matsumoto, N., Hasegawa, M., Fukui, M., Mukaida,N., Kinoshita, T., and Suda, T.: Fas ligand induces cell-autonomousNF-kappa B activation and IL-8 production by a mechanism distinct from that of TNF-alpha. J.Biol. Chem., 2004, 279:46415-23.

Umemura, M., Kawabe, T., Shudo, K., Kidoya, H., Fukui, M., Asano, M.,Iwakura, Y., Matsuzaki, G., Imamura, R., and Suda, T.: Involvement ofIL-17 in Fas ligand-induced inflammation. Int.Immunol.,  2004, 16:1099-108.

Wang, Y., Hasegawa, M., Imamura, R., Kinoshita, T., Kondo, C., Konaka,K., Suda, T.: PYNOD, a novel Apaf-1/CED4-like protein is an inhibitor ofASC and caspase-1. Int.Immunol., 2004, 16:777-86.

Nakamoto Y, Suda T, Momoi T, and Kaneko S.: Differentprocarcinogenic potentials of lymphocyte subsets in a transgenic mouse model ofchronic hepatitis B. Cancer Res., 2004, 64:3326-3333

Fukui M, Imamura R, Umemura M, Kawabe T, Suda T.: Pathogen-associated molecular patterns sensitize macrophages to Fas ligand-induced apoptosis and IL-1 beta release. J. Immunol., 2003, 171:1868-1874.

Tachiiri, A., Imamura, R., Wang, Y., Fukui, M., Umemura, M., and Suda, T.: Genomic structure and inducible expression of the IL-22 receptor alpha chain in mice. Gene. Immun., 2003, 4:153-159

Nakamoto, Y. Kaneko, S., Fan, H., Momoi, T., Tsutsui, H., Nakanishi, K.,Kobayashi, K., and Suda, T.: Prevention of Hepatocellular CarcinomaDevelopment Associated with Chronic Hepatitis by Anti-Fas Ligand AntibodyTherapy. J. Exp. Med., 2002, 196:1105-1111

Fukuyama H, Adachi M, Suematsu S, Miwa K, Suda T, Yoshida N, Nagata S.: Requirement of Fas expression in B cells for tolerance induction. Eur. J. Immunol., 2002, 32:223-30.

Shudo, K., Kinoshita, K., Imamura, R., Fan, H., Hasumoto, K., Tanaka, M.,Nagata, S., and Suda, T.: The membrane-bound but not the soluble form ofhuman Fas ligand is responsible for its inflammatory activity. Eur.J. Immunol., 2001, 31:2504-2511


–Ɖu‰ŠÇ§ŒäŒ¤‹†•ª–ìƒz[ƒ€ƒy[ƒW‚É–ß‚é

@